<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04575311</url>
  </required_header>
  <id_info>
    <org_study_id>ARC-11</org_study_id>
    <nct_id>NCT04575311</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arcus Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arcus Biosciences, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose Study to Investigate&#xD;
      the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will evaluate minimum of 2 dose levels of AB680 in 8 participants per cohort.&#xD;
      Cohorts will be gender-balanced to the extent possible, and will be randomized 3:1, active vs&#xD;
      placebo, respectively.&#xD;
&#xD;
      The participants will be closely observed to monitor the general tolerability of AB680.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>From First Dose Date to 15 Days After the Last Dose of AB680</time_frame>
    <description>Number of Participants with TEAEs as Assessed by CTCAE v5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AB680 Peak Plasma Concentration (Cmax)</measure>
    <time_frame>From First Dose Date to 15 Days After the Last Dose of AB680</time_frame>
    <description>Cmax as Measured by the Area Under Concentration-Time Curve from Plasma Collection and Analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AB680 Time of Peak Concentration (Tmax)</measure>
    <time_frame>From First Dose Date to 15 Days After the Last Dose of AB680</time_frame>
    <description>Tmax as Measured by the Time to Maximum Concentration-Time Curve from Plasma Collection and Analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic (PD) Effects of AB680</measure>
    <time_frame>From First Dose Date to 15 Days After the Last Dose of AB680</time_frame>
    <description>Enzymatic Activity of CD73 Measured in Participant Blood Samples.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Active: Dose Escalation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a single oral dose of AB680 at one of two ascending dose levels. Assignment to receive AB680 or matching placebo will be random.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo: Dose Escalation</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching placebo as a single oral dose. Assignment to receive AB680 or matching placebo will be random.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AB680</intervention_name>
    <description>AB680 is a Cluster of Differentiation (CD)73 Inhibitor</description>
    <arm_group_label>Active: Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching Placebo</description>
    <arm_group_label>Placebo: Dose Escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 55 years, inclusive, at screening&#xD;
&#xD;
          -  Body mass index 19 to 30 kg/m2&#xD;
&#xD;
          -  Willing and able to sign informed consent&#xD;
&#xD;
          -  Negative tests for hepatitis B surface antigen, anti-hepatitis C virus, and human&#xD;
             immunodeficiency virus (HIV)-1 and HIV-2 antibody at screening&#xD;
&#xD;
          -  Healthy as determined by pre-study screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of clinically significant drug and/or food allergies&#xD;
&#xD;
          -  Positive drug and alcohol screen at screening and (each) admission to the clinical&#xD;
             research center.&#xD;
&#xD;
          -  Participation in a drug study within 60 days prior to (the first) drug administration&#xD;
             in the current study. Participation in more than 4 other drug studies in the 12 months&#xD;
             prior to (the first) drug administration in the current study&#xD;
&#xD;
          -  Participants who have significant infection or known inflammatory process on screening&#xD;
             or admission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Monitor</last_name>
    <phone>510-694-6200</phone>
    <email>clinicaltrials@arcusbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nucleus Network</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Lickliter, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

